Reference is made to the merger between Aker BioMarine ASA (the "Company") and
Aker Capital NewCo AS ("MergerCo"), an indirect wholly-owned subsidiary of Aker
ASA ("Aker"), announced on 16 July 2026 and approved by an extraordinary general
meeting of the Company on 17 August 2026 (the "Merger").
As a preparatory step for completion of the Merger, Aker Capital AS ("Aker
Capital"), a wholly-owned subsidiary of Aker and a legal person closely
associated with Frank O. Reite, a member of the board of the Company, has today
transferred all of its 69,065,940 shares in the Company, equal to approximately
78.73% of the shares and votes in the Company, to MergerCo, a wholly-owned
subsidiary of Aker Capital. Finanstilsynet (the Financial Supervisory Authority
of Norway) has pursuant to section 6-2 (3) of the Norwegian Securities Trading
Act granted an exemption from the mandatory offer obligation for the transfer.
As previously announced, Aker Capital is also party to a forward contract with
respect to 10,707,629 shares in the Company, comprising the shares for which
acceptances were received under Aker Capital's optional cash offer for all
shares in the Company announced on 16 July 2026. The shares underlying the
forward contract represent approximately 12.21% of the shares and votes in the
Company.
This information is subject to the disclosure requirements pursuant to Article
19 of Regulation EU 596/2014 (the EU Market Abuse Regulation) and sections 4-2
and 5-12 of the Norwegian Securities Trading Act. Please refer to the attached
PDMR form for further details.
ttached\
PDMR form for further details. \